Relief and Renexxion terminate merger talks
Despite a non-binding letter of intent signed in November last year, the companies have mutually decided to discontinue negotiations after failing to meet critical conditions within the set
Aprea Therapeutics has signed a material transfer agreement (MTA) with MD Anderson Cancer Center to explore APR-1051 for head and neck squamous cell carcinoma (HNSCC).